<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501683</url>
  </required_header>
  <id_info>
    <org_study_id>KG2105264</org_study_id>
    <nct_id>NCT00501683</nct_id>
  </id_info>
  <brief_title>A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers</brief_title>
  <official_title>A Mass Balance Study to Investigate the Metabolic Disposition of a 400 mg Single, Oral Dose of GSK189075 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the relative amounts of GSK189075 that are found in samples of blood,
      urine, and feces of healthy male volunteers. Results of the study will be used to understand
      how the drug is converted in the body and how it is eliminated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory tests to determine the amount of radiolabelled drug that is found in blood, urine, and feces. Blood samples at Days 1-5.</measure>
    <time_frame>at Days 1-5.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine &amp; Fecal collection at Day -1 &amp; days 1-5.</measure>
    <time_frame>at Day -1 &amp; days 1-5.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs), vital signs, ECGs and clinical laboratory assessments at each day for up to 10 days</measure>
    <time_frame>at each day for up to 10 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiolabelled GSK189075</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are a healthy, non-smoking male.

          -  Are 30 to 55 years old, inclusive.

          -  Have a Body Mass Index (BMI) between 19-30 kg/m2, inclusive; and a body weight &gt;110
             lbs.

          -  Have a history of regular bowel movements (at least 4 times per week).

          -  Are willing and able to provide written informed consent before the start of any
             study-related procedures.

        Exclusion Criteria:

          -  Have any significant laboratory abnormality or history of liver or kidney disease.

          -  Have any significant abnormality in your electrocardiograms (ECG) which are recordings
             of your heart rhythm.

          -  Have a current condition(s) that alters normal gastrointestinal (GI) function (such as
             constipation or removal of your gallbladder).

          -  Have an illness that requires treatment by a physician in the 30 days before screening
             or a fever and illness in the 5 days before dosing.

          -  Have blood pressure that is outside the normal range.

          -  Have a resting pulse rate that is outside the normal range.

          -  Have had surgery within 3 months before screening, unless approved by the GSK medical
             monitor.

          -  Have a drug allergy which the investigator feels would make it unsafe for you to
             participate in the study.

          -  Have a history of or current abuse of alcohol.

          -  Have a history of or current use of illicit drugs, or a positive drug screen.

          -  Have used tobacco products within 3 months prior to screening or have a positive
             cotinine test result.

          -  Are unable to refrain from foods or beverages containing coffee, tea, or chocolate for
             72 hours before dosing with study drug and until 24 hours after dose.

          -  Have a positive test for human immunodeficiency virus (HIV) antibody or hepatitis B
             surface antigen or hepatitis C antibody.

          -  Have taken prescription or non-prescription drugs, including vitamins, herbal
             products, or plant-derived supplements (including St John's Wort) within 14 days (or
             less than 5 half-lives) before the first dose of study medication, unless approved by
             the GSK medical monitor

          -  Have participated in an investigational drug study within the 30 days before
             screening, or participated within the last 12 months in a study with another radio
             labeled drug product.

          -  Have a total radiation exposure from the previous 3-year period that is over 10 mSv
             (either from your work or through participation in other research studies). Clinical
             (therapeutic or diagnostic) exposure will not be included.

          -  Have donated blood (450 mL or more) within the previous 12 weeks.

          -  Are in an occupation which requires monitoring for radiation exposure, nuclear
             medicine procedures or have had excessive x-rays within the past 12 months.

          -  Are not able to follow the study directions.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolite profiling</keyword>
  <keyword>excretion,</keyword>
  <keyword>radioactivity,</keyword>
  <keyword>pharmacokinetic,</keyword>
  <keyword>mass balance,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

